Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Published:2017-02-09 Issue:9 Volume:58 Page:2240-2242
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Maiti Abhishek¹²,Cortes Jorge²,Ferrajoli Alessandra²,Estrov Zeev²,Borthakur Gautam²,Garcia-Manero Guillermo²,Jabbour Elias²,Ravandi Farhad²,O’Brien Susan³,Kantarjian Hagop²

Affiliation:

1. Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, TX, USA;

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

3. Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA

Funder

ChemGenex Pharmaceuticals, Ltd

Teva Pharmaceutical Industries Ltd.

CML P01

NCI

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1283030

Reference15 articles.

1. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

2. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

3. How I treat CML blast crisis

4. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications;European Journal of Medical Research;2024-05-04

2. Telomerase Inhibition in the Treatment of Leukemia: A Comprehensive Review;Antioxidants;2024-03-30

3. Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis;Journal of Pharmacy and Pharmacology;2023-06-13

4. Developing therapeutic approaches for chronic myeloid leukemia: a review;Molecular and Cellular Biochemistry;2022-10-10

5. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review;Expert Review of Hematology;2022-05-04